Ashwin Kashyap, M.D.
"Dr. Kashyap was everything I'd hope my doctor would be ... courteous, understanding, respectful and truly showing an interest in my health."
2005, American Board of Internal Medicine, Hematology
2004, American Board of Internal Medicine, Medical Oncology
2001, American Board of Internal Medicine
1980-1985, Royal Free Hospital School of Medicine (now University College London), London University, London, England
1977-1979, Harrow College of Higher Education (now Westminster University), London, England
1992-1993, Hematology, Research, University of Rochester, Rochester, NY
1991-1992, Medical Oncology, Clinical
1990-1991, Hematology, Clinical
1989-1990, Chief Resident, Internal Medicine, University of Rochester, Rochester, NY
1988-1989, Resident, Internal Medicine, University of Rochester, Rochester, NY
1986-1988, Family Medicine, Williamstown Hospital, Melbourne, Victoria, Australia
1985-1986, Medicine and Surgery, University College London, London University, London, England
2020-present, Physician and Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Thousand Oaks, CA
2015-2016, Chief of Medicine, Los Robles Hospital, Thousand Oaks, CA
2005-2007, Chair, Simi Valley Hospital Cancer Committee, Simi Valley, CA
1999-2001, Physician, Department of Informatics, City of Hope, Duarte, CA
1994-2001, Physician, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
1989-1990, Chief Resident Internal Medicine, University of Rochester, Rochester, NY
2000, Fellow, American College of Physicians
1992, NIH Institutional Fellowship Research Award
1985, Certificate of Merit in Pathology
1982, Distinction in Biochemistry
1981, Certificate of Merit in Biochemistry
Fellow of the American College of Physicians
Member of the American Society of Hematology
Member of American Society for Clinical Oncology
Member of European Hematology Association
Member SWOG Bone Marrow and Stem Cell Transplant Committee
Member of the American Society for Blood and Marrow Transplantation
- Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar J, Verburg R, Szer J, Taylor K, Joske D, Rule S, Bingham SJ, Emery P, Burt RK, Lowenthal RM, Durez P, McKendry RJ, Pavletic SZ, Espigado I, Jantunen E, Kashyap A, Rabusin M, Brooks P, Bredeson C, Tyndall A.
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. Journal of Rheumatology. 2004 Mar;31(3):482-8. - Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin RE. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biology of Blood and Marrow Transplantation. 2003 Nov; 9(11):722-4.
- Kashyap A, Wingard J, Cagnoni P, Tarantolo S, Fernandez H, Hu W, Niland J, Vaughan WP, Jones RP, Blume K, Champlin R, Forman SJ, Andersson BS. Intravenous (IV) vs Oral Busulfan (BU) as Part of a Bu/Cy (Cyclosphosphamide) Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Decreased Incidence of Hepatic Veno-Occlusive Disease (VOD), VOD related Mortality and Overall 100-Day Mortality.
Biology of Blood and Marrow Transplantation. 2002;8(9):493-500. - Fassas A, Passweg PR, Anagnostopoulos A, Kazis A, Kozak T, Carreras E, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Nagore FJ, Besalduch J, Dentamaro T, Fouillard L, Hertenstein B, Marrosu M, Musso M, Papineschi F, Rowe J, Saccardi R, Gratwohl A, Tyndall A. Autoimmune Disease Working Party of the EBMT. Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Retrospective Multicenter Study. Journal of Neurology. 2002 Aug; 249(8):1088-97.
- Andersson BS, Kashyap A, Gian V, Wingard J, Fernandez H, Cagnoni P, Jones R, Tarantolo S, Hu W, Blume K, Forman SJ, Champlin RE. Conditioning Therapy with Intravenous Busulfan and Cyclophosphamide (IV BuCy2) for Hematologic Malignancies Prior to Allogeneic Stem Cell Transplantation. A phase II study. Biology of Blood and Marrow Transplantation. 2002; 8(3):145-54.
- Kashyap A, Snowden J. Considerations in the Selection of an Appropriate Conditioning Regimen for the Treatment of Rheumatoid Arthritis by Autologous Peripheral Blood Stem Cell Transplantation. The Journal of Rheumatology 2001; 28 Suppl 64:39-41.
- Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, Westervelt P, Trinkaus K, Goodnough LT, Hayashi RJ, Parker P, Forman SJ, DiPersio JF. Treatment of Steroid Resistant Acute Graft-Versus-Host Disease with Anti-Thymocyte Globulin. Bone Marrow Transplant 2001 May; 27(10):1059-64.
- Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, Finke J, Peter HH, van Laar J, Breedveld FC, Fibbe WE, Farge D, Gluckman E, Locatelli F, Martini A, van den Hoogen F, van de Putte L, Schattenberg AV, Arnold R, Bacon PA, Emery P, Espigado I, Hertenstein B, Hiepe F, Kashyap A, Kotter I, Marmont A, Martinez A, Pascual MJ, Gratwohl A, Prentice HG, Black C, Tyndall A. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001 Jun;60(6):577-84.
- Bhatia S, Louie A, Bhatia R, O’Donnell M, Fung H, Kashyap A, Krishnan A, Molina A, Nademanee A, Niland J, Parker P, Snyder D, Spielberger R, Stein A, Forman SJ. Solid Cancers Following Bone Marrow Transplant. J Clin Oncol 2001; 19: 464-471.
- Bensinger W, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, Kashyap A, Flowers MED, Lilleby K, Chauncey T, Storb R, Blume K, Heimfield S, Rowley S, Appelbaum F. Transplantation of Bone Marrow as Compared with Peripheral Blood Cells from HLA Identical Relatives in Patients with Hematologic Cancers. New England Journal of Medicine 2001, 344; 175-181.
- Molina A, Popplewell L, Kashyap A, Nademanee A. Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center. Clin Transplant. 2000:317-42.
- Openshaw H, Lund B, Kashyap A, Atkinson R, Sniecinski I, Weiner LP, Forman SJ. Peripheral Blood Stem Cell Transplant in Multiple Sclerosis with Busulfan and Cyclophosphamide Conditioning: Report of Toxicity and Immunological Monitoring. Biology of Blood and Marrow Transplantation 2000; 6:563-575.